MedPal AI (LSE:MPAL) has reported a significant expansion in its business, with annualised recurring revenue increasing to approximately £8.6 million only nine months after launching its dispensing operations in October 2025. July 2026 marked the first month in which all three of the group’s core revenue streams were fully operational, resulting in its strongest monthly trading performance to date. Income was generated from NHS prescription dispensing, private GLP-1 weight management services under the New Health brand and recurring software subscriptions through the recently acquired eMARx platform.
Prescription volumes within the NHS business reached a new monthly high, supporting an annualised revenue run rate of more than £5.5 million. Meanwhile, the New Health division generated annualised private prescription revenue exceeding £2.2 million after only three weeks of marketing activity, demonstrating early demand for its weight management services.
The acquisition of eMARx has added approximately £843,000 in annualised recurring software revenue, providing MedPal AI with a high-margin SaaS income stream. Management intends to expand revenue opportunities by cross-selling products and services across its growing customer base, allowing multiple offerings to be delivered through a single client relationship.
The company also completed the acquisition of eMARx using a combination of cash and newly issued shares. In addition, advisory fees were settled through the issue of 928,570 new ordinary shares, bringing the total number of voting rights to 778,042,430. MedPal AI said these transactions strengthen its platform as it continues to build an integrated AI-driven healthcare ecosystem spanning pharmacy services, digital health and care-home technology.
More about MedPal AI Plc
MedPal AI plc is an AI-focused digital healthcare company operating across pharmacy, healthcare software and patient services. Its business includes NHS Distance Selling Pharmacy hubs, the New Health GLP-1 weight management clinic, a business-to-business pharmacy supply operation for care homes and the eMARx electronic medication administration platform.
The company is also developing Juno, an AI-powered healthcare assistant built using Anthropic’s Claude model, as part of its wider vision to create an integrated Health OS platform connecting prescribing, dispensing, medication management, delivery and patient support. Listed on both AIM and the Frankfurt Stock Exchange, MedPal AI generates recurring revenue from NHS and private prescriptions, software subscriptions and digital healthcare services.
Leave a Reply